Carbon dioxide laser versus cold-steel supraglottoplasty: A comparison of post-operative outcomes.
Autor: | Yeung JC; Department of Otolaryngology - Head & Neck Surgery, McGill University, Canada; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA. Electronic address: jeffrey.yeung@mcgill.ca., Ali SO; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA., McKeon MG; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA., Grenier S; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA., Kawai K; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA., Rahbar R; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA; Department of Otology and Laryngology, Harvard Medical School, USA., Watters KF; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, USA; Department of Otology and Laryngology, Harvard Medical School, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | International journal of pediatric otorhinolaryngology [Int J Pediatr Otorhinolaryngol] 2020 Mar; Vol. 130, pp. 109843. Date of Electronic Publication: 2019 Dec 24. |
DOI: | 10.1016/j.ijporl.2019.109843 |
Abstrakt: | Objective: Supraglottoplasty is the mainstay of surgical treatment for laryngomalacia, and is commonly performed via two methods: cold steel or carbon dioxide (CO Design: Retrospective cohort of pediatric patients (age < 18 years) undergoing supraglottoplasty at a tertiary care pediatric hospital. The primary exposure was the surgical instrument(s) used during supraglottoplasty. The primary outcome was prolonged intensive care unit (ICU)-stay (defined as >24 h). Results: 155 cases were eligible for inclusion. Fifty-eight (37.4%) patients had a comorbid condition. Common indications for surgery included feeding difficulty (56.1%), severe respiratory distress (33.5%), and obstructive sleep apnea (25.2%). CO Conclusions: CO Competing Interests: Declaration of competing interest None. (Copyright © 2019 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |